Fiche centre
Novartis Investigative Site
León — Mexico
Essais liés5clinical trials
VilleLeónlocalisation
PaysMexicolocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05126277
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| ianalumab s.c. q4w | Lupus | Phase 3 | NCT05126277 | SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT06711887 | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05624749 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | SIRIUS-SLE LTE — Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |